This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many ... aiming to cut injection volume by half and result in fewer injections in particular ...
Hosted on MSN1mon
AbbVie retains Humira market share above 70%: reportAbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70% ... The anti-inflammatory injection, also known as adalimumab, lost its U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback